Biosino Bio-Technology and Science Incorporation (HKG:8247)
4.280
+0.190 (4.65%)
At close: Jan 30, 2026
HKG:8247 Revenue
Biosino Bio-Technology and Science Incorporation had revenue of 95.82M CNY in the half year ending June 30, 2025, a decrease of -31.14%. This brings the company's revenue in the last twelve months to 225.06M, down -20.69% year-over-year. In the year 2024, Biosino Bio-Technology and Science Incorporation had annual revenue of 263.07M, down -9.00%.
Revenue (ttm)
225.06M CNY
Revenue Growth
-20.69%
P/S Ratio
2.51
Revenue / Employee
477.83K CNY
Employees
471
Market Cap
619.35M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 263.07M | -26.00M | -9.00% |
| Dec 31, 2023 | 289.07M | -84.00M | -22.52% |
| Dec 31, 2022 | 373.07M | 24.85M | 7.14% |
| Dec 31, 2021 | 348.23M | 22.97M | 7.06% |
| Dec 31, 2020 | 325.26M | -72.15M | -18.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi XDC Cayman | 5.58B |
| Adicon Holdings | 2.98B |
| Kindstar Globalgene Technology | 998.42M |
| Yunkang Group | 706.95M |
| Mega Genomics | 171.61M |
| Guanze Medical Information Industry (Holding) | 161.70M |
| King International Investment | 77.50M |
| China Biotech Services Holdings | 76.93M |